Skip to main content

Novo Nordisk says high-dose experimental obesity pill leads to 15% weight loss

Novo Nordisk's pill is an oral version of semaglutide, the active ingredient in the Danish company's blockbuster weight loss injections Ozempic and Wegovy.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.